Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab-nivolumab versus regorafenib or TAS-102 in later-line metastatic colorectal cancer
2023-503797-21-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing Relatlimab + nivolumab fixed-dose combination, Regorafenib and Trifluridine + tipiracil (3 arms). Primary endpoints: Overall survival in PD-L1 CPS >= 1 population and Overall survival in all randomized participants. Started Aug 2022; status: completed.
02
Drugs
nivolumab + relatlimabregorafenibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-503797-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503797-21-00.